"Ranibizumab" Related Products

Ranibizumab Bioassay Kit

Cat.No.: Kit-1612
Product Overview: These assays utilize Enzyme Fragment Complementation (EFC) technology, where the b-galactosidase (b-gal) enzyme is split into two fragments: ProLink (PK) and Enzyme Acceptor (EA). Independently these fragments have no b-gal activity; however, when forced to complement through protein-protein interactions, they form an active b-gal enzyme.
The Ranibizumab Bioassay can be used to detect ligand-induced dimerization of two subunits of a receptor-dimer pair. This assay detects VEGF-Ainduced homodimeriziaton of the kinase insert domain (KDR), also known as VEGFR2 receptor. The cells have been engineered to co-express KDR fused to PK, and another KDR construct fused to EA. Activation of the KDR receptor through VEGF-A leads to receptor dimerization, which is an essential event in the receptor's signaling cascade. Receptor dimerization forces the two enzyme fragments to complement, resulting in the formation of a functional b-gal enzyme. The enzyme hydrolyzes a substrate to generate a chemiluminescent signal. Ranibizumab binds to and inactivates the VEGF-A protein, preventing VEGF from activating the VEGFR2 receptors. This leads to an inhibition of the signaling event and therefore a reduction in signal.
Description: Ranibizumab Bioassay kits provide a functional, robust, highly sensitive, and easy-to-use cell-based assay to study ranibizumab potency and neutralizing antibodies. The bioassay kits contain all the reagents needed for a complete assay including cells, detection reagents, cell plating reagent, positive control agonist, and assay plates. The pre-validated, frozen cells have been manufactured for single-use and are provided in a ready-to-assay format that saves time and adds convenience.
Storage: HEK 293 KDR/KDR Bioassay Cells:
Cells are shipped on dry ice and should arrive in a frozen state. To ensure maximum cell viability, thaw the vials as soon as possible upon receipt.
If continued storage of the frozen vials is necessary, store as follows: ƒ
Short term (24 hours or less): Store vials at -80°C immediately upon arrival. (DO NOT store at -80°C for more than 24 hours). ƒ
Long term (greater than 24 hours): Vials should ONLY be stored in the vapor phase of liquid nitrogen (LN2).

Bioassay Detection Kit
Store at -20°C. Once thawed, the detection reagents can be kept at 4°C for up to 4 days. For longer storage (up to the expiration date listed on the kit certificate of analysis), the reagent should be aliquoted and stored at -20°C until needed. Avoid multiple freeze-thaw cycles.
To make aliquots suitable for testing one assay plate each, 1mL of Detection Reagent 1 per aliquot can be dispensed and frozen down. 4mL of Detection Reagent 2 per aliquot can be dispensed and frozen down separately. Do not mix the two reagents during aliquoting.

AssayComplete Cell Plating Reagent 0
Once thawed, the Cell Plating Reagent can be stored at 4°C for up to 4 weeks. For longer storage (up to the expiration date listed on the kit certificate of analysis), the reagent should be aliquoted and stored at -20°C until needed. Avoid multiple freeze-thaw cycles. To make aliquots suitable for testing one assay plate each, 30mL of reagent per aliquot can be dispensed and frozen down.

Protein Dilution Buffer
Once thawed, the Protein Dilution Buffer can be stored at 4°C for up to 4 weeks. For longer storage (up to the expiration date listed on the kit certificate of analysis), the reagent should be aliquoted and stored at -20°C until needed. Avoid multiple freeze-thaw cycles. To make aliquots suitable for testing one assay plate each, 10 mL of reagent per aliquot should be dispensed and frozen down. This amount may vary depending on your stock sample concentrations and should be adjusted accordingly.

Recombinant Human VEGF165 Control Agonist
Store at -20°C until ready to use (up to the expiration date listed on the kit certificate of analysis). Centrifuge the vial prior to opening to maximize recovery. Reconstitute to a concentration of 100 μg/mL by adding 100 μL of Protein Dilution Buffer. Reconstituted ligand is stable for 12 months at -20 to -80°C, or 1 week at 2-8 °C.

96-well Tissue Culture Treated Plates
Store at room temperature.
Kit Components: HEK 293 KDR/KDR Bioassay Cells: 2 vials
Bioassay Detection Kit
Detection Reagent 1: 2 mL
Detection Reagent 2: 8 mL
AssayComplete Cell Plating Reagent 0: 1 X 100 mL
Protein Dilution Buffer: 1 X 50 mL
Control Agonist (VEGF165): 1 vial
96-Well Opaque-Bottom TC Treated, Sterile Plates w/Lid: 2 plates
Materials Required but Not Supplied: Single and Multichannel Micro-Pipettors and Pipette Tips
Multimode or Luminescence Plate Reader
V-Bottom 96-Well Compound Dilution Plates
Disposable Reagent Reservoir
Assay Protocol: Bioassay Cell Preparation:
The following protocol is for thawing and plating frozen HEK 293 KDR/KDR Bioassay cells from cryovials.
1. Before thawing the cells, ensure that all the necessary materials required are set up in the tissue culture hood. This includes:
a. One 25 mL reagent reservoir.
b. One 15 mL conical tube.
c. A micropipettor (P1000) set to dispense 1 mL.
d. A multichannel pipette and tips set to dispense 80 μL.
e. A bottle of Cell Plating Reagent 0 (CP0, pre-warmed in a 37˚C water bath for 15 minutes).
f. A white-walled, opaque-bottom 96-well assay plate.
2. Dispense 10 mL of CP0 into the 15 mL conical tube.
3. Remove the cryovial from liquid nitrogen and immediately place in dry ice.
DO NOT use heated water bath to thaw the vial. Wipe down the cryovial quickly with 70% EtOH, and bring it into the tissue culture hood right away. DO NOT touch the sides or bottom of the vial to avoid thawing of the cell pellet through body heat.
4. Thaw the pellet by immediately adding 1 mL (using P1000) of pre-warmed CP0 from the 15 mL conical tube to the cryovial, thawing the cell pellet. The medium should be added slowly along the side of the wall of cryovial tube. Mix the cells gently by pipetting up and down several times to break up any clumps. Transfer the cell suspension to the conical tube containing the remaining 9 mL of CP0. Remove any medium/suspension left in the tube to ensure complete recovery of all the cells from the vial.
5. Mix the tube by inversion to ensure the cells are properly mixed in the medium without creating any froth in the suspension and immediately pour the suspension into the 25 mL reservoir.
6. Add 80 μL of cells to each well of the 96-well assay plate using the multichannel pipette. Gently place the assay plate in a tissue culture incubator set to 37˚C, 5% CO2 . Ligand may be added to the cells immediately (0-4 hours after plating).

Ligand Preparation
The following protocol is designed for testing purified biologics. The assays can also be run in the presence of high levels of serum or plasma without significantly impacting assay performance. Therefore, standard curves of control can typically be prepared in neat serum or plasma and added directly to cells without further dilution. For the best results, the optimized minimum required dilution (MRD) of crude samples should be empirically determined.
1. Prepare the reference agonist (VEGF165) dose response curve, which will serve as a positive control in this assay. Agonist is prepared at 5 X the desired final concentration as it will be diluted by adding 20 μL to 80 μL of media present in the assay plate.
a. Add 200 μL of Protein Dilution Buffer (PDB) to wells A2 to A12 of a master dilution plate (e.g. a V-bottom polypropylene 96-well dilution plate).
b. Add 100 μL of PDB to the VEGF165 vial containing 10 μg of lyophilized powder to make a 100 μg/mL stock solution.
c. Add 190 μL of PDB to well A1 of the master dilution plate. Add 10 μL of the 100 μg/mL VEGF165 stock to this well. Mix thoroughly by pipetting up and down several times. This results in an 5 μg/mL solution (5 X the final 1 μg/mL curve top).
d. Using a clean tip, transfer 100 μL from well A1 into well A2 and mix by pipetting up and down several times. Replace the pipette tip and transfer 100 μL from well A2 into well A3. Mix by pipetting up and down several times. Repeat this process until well A11 is reached, resulting in an eleven point, 1:3 dilution series. No ligand is transferred to column 12 as this will serve as a negative control.
2. Agonist challenge for biosimilar curves: The EC80 of the VEGF165 was determined to be approximately 50 ng/mL. If VEGF165 from a different vendor is used, the EC80 should be determined empirically prior to running samples. Prepare the agonist challenge at 10 X the desired final concentration. For enough agonist challenge for a single biosimilar curve run in triplicate, dilute 7.5 μL of the 100 μg/mL stock with 1.5 mL of PDB in an Eppendorf tube.
3. Prepare ranibizumab reference curve. Ranibizumab is prepared at 10 X the desired final concentration. The suggested final concentration of the top dose for ranibizumab is 10 μg/mL.
a. Add 225 μL of PDB to well B2, 200 μL to wells B3, B4, B9, B10 & B12, 150 μL to wells B5 to B8, and finally 180 μL to wells B11.
b. Add 180 μL of ranibizumab prepared at 10 X the desired final concentration (10 μg/mL) to well B1 of this row on the master dilution plate. To make this, add 3 μL of ranibizumab from a stock of 6 mg/mL to 177 μL of PDB.
c. Using a clean tip, transfer 25 μL from well B1 into well B2 for a 1:10 dilution, and mix by pipetting up and down several times. Replace the pipette tip and transfer 100 μL from well B2 into well B3 for a 1:3 dilution. Mix by pipetting up and down several times. Repeat this process for well B4. Then transfer 150 μL from well B4 to well B5 and mix for a 1:2 dilution. Continue transferring 150 μL with a clean pipette and mix until well B8 is reached. Transfer 100 μL from well B8 to well B9 for a 1:3 dilution and repeat for well B10. Then transfer 20 μL from well B10 to B11 for a 1:10 dilution. No antibody is transferred to well B12 as this will serve as a negative control.
4. Transfer 100 μL from the ranibizumab curve prepared in step 3, to a new row on the master dilution plate (e.g. a V-bottom polypropylene 96-well dilution plate).
5. Add 100 μL of VEGF165 agonist challenge prepared above in step 2, to columns 1-11 of the ranibizumab row of the pre-mixing plate. 100 μL of PDB can be added to the negative control well of column 12 to maintain equal volumes in all wells.
6. Mix the contents of the pre-mixing plate wells thoroughly by pipetting up and down with a clean tip for each well, or with a multi-channel pipette.
7. Remove the assay plate from the 37°C, 5% CO2 incubator and bring into the tissue culture hood.
8. Add 20 μL from the agonist reference curve prepared in step 1 on the master dilution plate, to the appropriate wells of the assay plate.
9. Add 20 μL from each well of the ranibizumab plus VEGF165 pre-mixed curve from the master dilution plate to the appropriate wells of the assay plate.
10. Return the assay plate to the 37°C, 5% CO2 incubator and incubate overnight (16-18 hours).

Detection
1. Using a multichannel pipette, add 10 μL of Detection Reagent 1 to each well of the assay plate. Place the plate onto an orbital shaker at 350 rpm for 1 minute to cause even mixing.
2. Incubate the plate at room temperature for 15 minutes in the dark.
3. Using a multichannel pipette add 40 μL of Detection Reagent 2 to each well of the assay plate.
4. Incubate the plate at room temperature for 3 hours in the dark.
5. Read sample on a standard luminescence plate reader at 0.1 to 1 second/well for photomultiplier tube (PMT) readers or 5-10 seconds for imager.
Note: For crude biologic samples, gently removing the liquid from all wells and replacing with 100 µL of Cell Plating Reagent before the addition of the detection reagents can result in higher signal. Additional Cell Plating Reagent is necessary for this method.

Online Inquiry

Note: There will be extra charge for optional service!

Please input "biomart" as verification code. Please review Creative BioMart's privacy policy for more information

Optional requirements on this protein    +Expand

Price Inquiry

Welcome! For price inquiries, please feel free to contact us through the form below. We will get back to you as soon as possible.